Shasun Pharma in licensing pact with Debiopharm Group
Chennai-based Shasun Pharmaceuticals has entered into a licensing agreement with Swiss biopharmaceutical group Debiopharm for the manufacturing and commercialization of Huperzine-A, sending its shares up over 4 percent.
April 10, 2013 / 14:18 IST
Moneycontrol Bureau
Chennai-based Shasun Pharmaceuticals has entered into a licensing agreement with Swiss biopharmaceutical group Debiopharm for the manufacturing and commercialization of Huperzine-A, sending its shares up over 4 percent. Huperzine-A is used in Alzheimer's disease and according to Shasun, clinical studies have shown significant improvement in memory deficit and cognitive performance in patients. As per the terms of the deal, Shasun will be able to use Debiopharm technology to manufacture synthetic Huperzine-A and commercialize it in pharmaceutical and nutraceutical markets.The manufacturing technology involves a 10-stage chemical synthesis process and is a result of joint collaboration between Shasun's research centres in Chennai and UK, it said.Huperzine-A is commercially available through Shasun.Shasun Pharma shares were trading at Rs 68.05, up 4.2 percent on NSE in noon trade. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
